Fachbereich Veterinärmedizin



    Prävention der equinen Herpesvirus-Myeloenzephalopathie – Ist Heparin eine vielversprechende Option? Ein Fallbericht (2016)

    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Walter, Jasmin
    Seeh, Christoph
    Fey, Kerstin
    Bleul, Ulrich
    Osterrieder, Nikolaus (WE 5)
    Tierärztliche Praxis / Ausgabe G, Großtiere, Nutztiere; 44(5) — S. 313–317
    ISSN: 1434-1220
    Pubmed: 27652372
    Institut für Virologie

    Robert-von-Ostertag-Str. 7-13
    Gebäude 35
    14163 Berlin
    +49 30 838 51833

    Abstract / Zusammenfassung

    Equine herpesvirus myeloencephalopathy (EHM) is a severe manifestation of equine herpesvirus 1 (EHV-1) infection. Prevention and treatment of EHM during EHV-1 outbreaks is critical, but no reliable and tested specific medication is available. Due to the thromboischemic nature of EHM and due to the fact that EHV-1 entry in cells is blocked by heparin, it was hypothesized that this compound may be useful in reduction of EHM incidence and severity. Therefore, during an acute EHV-1 outbreak with the neuropathogenic G2254/D752 Pol variant, metaphylactic treatment with heparin to prevent EHM was initiated. Clinical signs were present in 61 horses (fever n = 55; EHM n = 8; abortion n = 6). Heparin (25000 IU subcutaneously twice daily for 3 days) was given to 31 febrile horses from day 10 of the outbreak, while the first 30 horses exhibiting fever remained untreated. Treatment outcome was analyzed retrospectively. Heparin-treated horses showed a lower EHM incidence (1/31; 3.2%) than untreated horses (7/30; 23.3%; p = 0.03). Results indicate that heparin may be useful for prevention of EHM during an EHV-1 outbreak. These promising data highlight the need for randomized and possibly blinded studies for the use of heparin in EHV-1 outbreaks.